Opinion|Videos|September 16, 2024
AE Management with Atezolizumab + Bevacizumab
Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share your thoughts on the data based on baseline varices from IMbrave 150.
- Concerning safety data, is this in line with you what you see in practice for the vp4 and baseline varices?
- How do you currently manage AEs seen in practice?
- Please share your thoughts on the data based on Child-Pugh A vs B for IMbrave 150.
- How do you consider immunotherapy to be different for Child-Pugh A vs B?
Advertisement
Related to this article
The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed/refractory multiple myeloma.
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5